New drug cocktail aims to stop esophageal cancer from coming back
NCT ID NCT05480384
First seen Jan 07, 2026 · Last updated May 13, 2026 · Updated 20 times
Summary
This study looks at whether a 1-year treatment with two drugs (Enhertu and nivolumab) can safely prevent cancer from returning in people with HER2-positive esophageal or stomach-junction cancer. Participants have already completed standard therapy (chemoradiation and surgery) but still had some cancer cells left. The main goal is to check for serious side effects and see how long people stay cancer-free.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Lifespan Cancer Institute
Providence, Rhode Island, 02903, United States
-
Weill Cornell Medicine/New York-Presbyterian
New York, New York, 10021, United States
Conditions
Explore the condition pages connected to this study.